Background/Aims: Rhapontigenin (RPG) is a stilben derivative and is known to bear several effects such as antiallergic, anticoagulative, hypoglycemic, antiangiogenic, and purgative. The investigation was conducted to evaluate the cardioprotective efficacy of RPG in rats having acute myocardial infarction (MI) induced by isoproterenol (ISO). Methods: Animals were divided into 6 groups: group I (control group), group II (ISO-treated), group III (1.0 mg/kg/day RPG and ISO-treated), group IV (2.5 mg/kg/day RPG and ISO-treated), group V (5.0 mg/kg/day RPG and ISO-treated), and group VI (treated with RPG 5.0 mg/kg/day). Various cardiac stress markers, including infarct size and heart/body weight index, were investigated in animals with ISO-induced MI, such as inducible nitric oxide synthase (iNOS), creatinine kinase (CK), lactate dehydrogenase (LD), cardiac troponin-T (CTT), superoxide dismutase (SOD), and malondialdehyde. INOS, p38, caspase-3, and connexin 43 expressions were analyzed in animals. Inflammatory mediators, tissue necrosis factor-α (TNF-α) and interleukin-6 (IL-6), were detected in serum of experimental animals. Results: Group I animals indicated normal levels of biochemical parameters, whereas group II animals indicated high levels of these parameters and successful induction of MI. Pretreatment of animal groups III, IV, and V with RPG revealed amelioration of infarct size, heart/body weight index, CK, LD, CTT in rats, whereas group VI animals were treated only with RPG (5.0 mg/kg/day) and not with ISO. Levels of TNF-α, IL-6, MD, SOD, p38, and iNOS expressions were significantly downregulated by RPG administration (5.0 mg/kg/day). Conclusion: RPG ameliorates MI caused by ISO in rats and provides cardioprotective effect, via anti-inflammatory, antioxidant, and antiapoptotic effect.

Keywords:
Cardioprotective, Myocardial infarction, Rhapontigenin, Oxidative stress, Isoproterenol
1.
Aronow WS. Epidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure.
Cardiol Rev
. 2006 May-Jun; 14(3): 108–24.
2.
Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study.
Lancet
. 1997 May; 349(9064): 1498–504.
3.
Chen SW, Tung YC, Jung SM, Chu Y, Lin PJ, Kao WW, et al. Lumican-null mice are susceptible to aging and isoproterenol-induced myocardial fibrosis.
Biochem Biophys Res Commun
. 2017 Jan; 482(4): 1304–11.
4.
Raish M. Momordica charantia polysaccharides ameliorate oxidative stress, hyperlipidemia, inflammation, and apoptosis during myocardial infarction by inhibiting the NF-κB signaling pathway.
Int J Biol Macromol
. 2017 Apr; 97: 544–51.
5.
Hašková P, Jansová H, Bureš J, Macháček M, Jirkovská A, Franz KJ, et al. Cardioprotective effects of iron chelator HAPI and ROS-activated boronate prochelator BHAPI against catecholamine-induced oxidative cellular injury.
Toxicology
. 2016 Sep; 371: 17–28.
6.
Yasuda J, Okada M, Yamawaki H. T3 peptide, an active fragment of tumstatin, inhibits H2O2-induced apoptosis in H9c2 cardiomyoblasts.
Eur J Pharmacol
. 2017 Jul; 807: 64–70.
7.
Geng ZH, Huang L, Song MB, Song YM. Protective effect of a polysaccharide from Salvia miltiorrhiza on isoproterenol (ISO)-induced myocardial injury in rats.
Carbohydr Polym
. 2015 Nov; 132: 638–42.
8.
E MP. Mopuri R, Pulaganti M, Kareem MA, Islam MS, K R DG, Irene M, Lu Y, Kodidhela LD: molecular assessment of protective effect of Vitex negundo in ISO induced myocardial infarction in rats.
Biomed Pharmacother
. 2017; 92: 249–53.
9.
Woudstra L, Biesbroek PS, Emmens RW, Heymans S, Juffermans LJ, van Rossum AC, et al. Lymphocytic myocarditis occurs with myocardial infarction and coincides with increased inflammation, hemorrhage and instability in coronary artery atherosclerotic plaques.
Int J Cardiol
. 2017 Apr; 232: 53–62.
10.
De Filippo K, Dudeck A, Hasenberg M, Nye E, van Rooijen N, Hartmann K, et al. Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation.
Blood
. 2013 Jun; 121(24): 4930–7.
11.
Rathore N, John S, Kale M, Bhatnagar D. Lipid peroxidation and antioxidant enzymes in isoproterenol induced oxidative stress in rat tissues.
Pharmacol Res
. 1998 Oct; 38(4): 297–303.
12.
Zhou R, Xu Q, Zheng P, Yan L, Zheng J, Dai G. Cardioprotective effect of fluvastatin on isoproterenol-induced myocardial infarction in rat.
Eur J Pharmacol
. 2008 May; 586(1-3): 244–50.
13.
Upaganlawar A, Gandhi H, Balaraman R. Isoproterenol induced myocardial infarction: protective role of natural products.
J Pharmacol Toxicol
. 2011; 6(1): 1–17.
14.
Zaragoza C, Gomez-Guerrero C, Martin-Ventura JL, Blanco-Colio L, Lavin B, Mallavia B, et al. Animal models of cardiovascular diseases.
J Biomed Biotechnol
. 2011; 2011: 497841.
15.
Ou L, Li W, Liu Y, Zhang Y, Jie S, Kong D, et al. Animal models of cardiac disease and stem cell therapy.
Open Cardiovasc Med J
. 2010 Nov; 4(1): 231–9.
16.
Davel AP, Brum PC, Rossoni LV. Isoproterenol induces vascular oxidative stress and endothelial dysfunction via a Giα-coupled β2-adrenoceptor signaling pathway.
PLoS One
. 2014 Mar; 9(3):e91877.
17.
Díaz-Muñoz M, Alvarez-Pérez MA, Yáñez L, Vidrio S, Martínez L, Rosas G, et al. Correlation between oxidative stress and alteration of intracellular calcium handling in isoproterenol-induced myocardial infarction.
Mol Cell Biochem
. 2006 Sep; 289(1-2): 125–36.
18.
Todd GL, Cullan GE, Cullan GM. Isoproterenol-induced myocardial necrosis and membrane permeability alterations in the isolated perfused rabbit heart.
Exp Mol Pathol
. 1980 Aug; 33(1): 43–54.
19.
Rajadurai M, Prince PS. Preventive effect of naringin on isoproterenol-induced cardiotoxicity in Wistar rats: an in vivo and in vitro study.
Toxicology
. 2007 Apr; 232(3): 216–25.
20.
Rajadurai M, Stanely Mainzen Prince P. Preventive effect of naringin on lipid peroxides and antioxidants in isoproterenol-induced cardiotoxicity in Wistar rats: biochemical and histopathological evidences.
Toxicology
. 2006 Dec; 228(2-3): 259–68.
21.
Rajadurai M, Stanely Mainzen Prince P. -Preventive effect of naringin on cardiac markers, electrocardiographic patterns and lysosomal hydrolases in normal and isoproterenol-induced myocardial infarction in Wistar rats.
Toxicology
. 2007 Feb; 230(2-3): 178–88.
22.
Anandan R, Mathew S, Sankar TV, Viswanathan Nair PG. Protective effect of n-3 polyunsaturated fatty acids concentrate on isoproterenol-induced myocardial infarction in rats.
Prostaglandins Leukot Essent Fatty Acids
. 2007 Mar; 76(3): 153–8.
23.
Panda VS, Naik SR. Cardioprotective activity of Ginkgo biloba Phytosomes in isoproterenol-induced myocardial necrosis in rats: a biochemical and histoarchitectural evaluation.
Exp Toxicol Pathol
. 2008 Aug; 60(4-5): 397–404.
24.
Rona G. Catecholamine cardiotoxicity.
J Mol Cell Cardiol
. 1985 Apr; 17(4): 291–306.
25.
Tang MK, Ren DC, Zhang JT, Du GH. Effect of salvianolic acids from Radix Salviae miltiorrhizae on regional cerebral blood flow and platelet aggregation in rats.
Phytomedicine
. 2002 Jul; 9(5): 405–9.
26.
Radhiga T, Rajamanickam C, Sundaresan A, Ezhumalai M, Pugalendi KV. Effect of ursolic acid treatment on apoptosis and DNA damage in isoproterenol-induced myocardial infarction.
Biochimie
. 2012 May; 94(5): 1135–42.
27.
Hasiah AH, Ghazali AR, Weber JF, Velu S, Thomas NF, Inayat Hussain SH. Cytotoxic and antioxidant effects of methoxylated stilbene analogues on HepG2 hepatoma and Chang liver cells: implications for structure activity relationship.
Hum Exp Toxicol
. 2011 Feb; 30(2): 138–44.
28.
Wilson MA, Rimando AM, Wolkow CA. Methoxylation enhances stilbene bioactivity in Caenorhabditis elegans.
BMC Pharmacol
. 2008 Aug; 8(1): 15.
29.
Roupe KA, Remsberg CM, Yáñez JA, Davies NM. Pharmacometrics of stilbenes: seguing towards the clinic.
Curr Clin Pharmacol
. 2006 Jan; 1(1): 81–101.
30.
Park EK, Choo MK, Yoon HK, Kim DH. Antithrombotic and antiallergic activities of rhaponticin from Rhei Rhizoma are activated by human intestinal bacteria.
Arch Pharm Res
. 2002 Aug; 25(4): 528–33.
31.
Lee JH, Kim JM, Kim C. Pharmacokinetic analysis of rhein in Rheum undulatum L.
J Ethnopharmacol
. 2003 Jan; 84(1): 5–9.
32.
Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia.
Kidney Int
. 1996 May; 49(5): 1304–13.
33.
Tiwari BK, Kumar D, Abidi AB, Rizvi SI. Efficacy of composite extract from leaves and fruits of medicinal plants used in traditional diabetic therapy against oxidative stress in alloxan-induced diabetic rats.
ISRN Pharmacol
. 2014 Mar; 2014: 608590.
34.
Jollow DJ, Mitchell JR, Zampaglione N, Gillette JR. Bromobenzene-induced liver necrosis. Protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite.
Pharmacology
. 1974; 11(3): 151–69.
35.
Bruce AF, Rothery S, Dupont E, Severs NJ. Gap junction remodelling in human heart failure is associated with increased interaction of connexin43 with ZO-1.
Cardiovasc Res
. 2008 Mar; 77(4): 757–65.
36.
Neumann J, Schmitz W, Scholz H, von Meyerinck L, Döring V, Kalmar P. Increase in myocardial Gi-proteins in heart failure.
Lancet
. 1988 Oct; 2(8617): 936–7.
37.
Niger C, Hebert C, Stains JP. Interaction of connexin43 and protein kinase C-delta during FGF2 signaling.
BMC Biochem
. 2010 Mar; 11(1): 14.
38.
Nishii K, Kumai M, Shibata Y. Regulation of the epithelial-mesenchymal transformation through gap junction channels in heart development.
Trends Cardiovasc Med
. 2001 Aug; 11(6): 213–8.
39.
Tasatargil A, Kuscu N, Dalaklioglu S, Adiguzel D, Celik-Ozenci C, Ozdem S, et al. Cardioprotective effect of nesfatin-1 against isoproterenol-induced myocardial infarction in rats: role of the Akt/GSK-3β pathway.
Peptides
. 2017 Sep; 95: 1–9.
40.
Singal PK, Beamish RE, Dhalla NS. Potential oxidative pathways of catecholamines in the formation of lipid peroxides and genesis of heart disease.
Adv Exp Med Biol
. 1983; 161: 391–401.
41.
Zaitone SA, Abo-Gresha NM. Rosuvastatin promotes angiogenesis and reverses isoproterenol-induced acute myocardial infarction in rats: role of iNOS and VEGF.
Eur J Pharmacol
. 2012 Sep; 691(1-3): 134–42.
42.
O’Brien PJ, Smith DE, Knechtel TJ, Marchak MA, Pruimboom-Brees I, Brees DJ, et al. Cardiac troponin I is a sensitive, specific biomarker of cardiac injury in laboratory animals.
Lab Anim
. 2006 Apr; 40(2): 153–71.
43.
Evran B, Karpuzoğlu H, Develi S, Kalaz EB, Soluk-Tekkeşin M, Olgaç V, et al. Effects of carnosine on prooxidant-antioxidant status in heart tissue, plasma and erythrocytes of rats with isoproterenol-induced myocardial infarction.
Pharmacol Rep
. 2014 Feb; 66(1): 81–6.
44.
Padmanabhan M, Prince PS. Preventive effect of S-allylcysteine on lipid peroxides and antioxidants in normal and isoproterenol-induced cardiotoxicity in rats: a histopathological study.
Toxicology
. 2006 Jul; 224(1-2): 128–37.
45.
Sharmila Queenthy S, Stanely Mainzen Prince P, John B. Diosmin prevents isoproterenol-induced heart mitochondrial oxidative stress in rats.
Cardiovasc Toxicol
. 2018 Apr; 18(2): 120–30.
46.
Pinto VD, Cutini GJ, Sartório CL, Paigel AS, Vassallo DV, Stefanon I. Enhanced beta-adrenergic response in rat papillary muscle by inhibition of inducible nitric oxide synthase after myocardial infarction.
Acta Physiol (Oxf)
. 2007 Jun; 190(2): 111–7.
47.
Li D, Qu Y, Tao L, Liu H, Hu A, Gao F, et al. Inhibition of iNOS protects the aging heart against beta-adrenergic receptor stimulation-induced cardiac dysfunction and myocardial ischemic injury.
J Surg Res
. 2006 Mar; 131(1): 64–72.
48.
Bredeson S, Papaconstantinou J, Deford JH, Kechichian T, Syed TA, Saade GR, et al. HMGB1 promotes a p38MAPK associated non-infectious inflammatory response pathway in human fetal membranes.
PLoS One
. 2014 Dec; 9(12):e113799.
49.
Owona BA, Njayou NF, Laufer SA, Schluesener HJ, Moundipa PF. Entada africana fraction CH₂Cl₂/MEOH 5% inhibits inducible nitric oxide synthase and pro-inflammatory cytokines gene expression induced by lipopolysaccharide in microglia.
BMC Complement Altern Med
. 2013 Oct; 13(1): 254.
50.
Chen P, Huang L, Zhang Y, Qiao M, Yuan Y. SiRNA-mediated PIAS1 silencing promotes inflammatory response and leads to injury of cerulein-stimulated pancreatic acinar cells via regulation of the P38MAPK signaling pathway.
Int J Mol Med
. 2010 Oct; 26(4): 619–26.
51.
Chen TL, Zhu GL, He XL, Wang JA, Wang Y, Qi GA. Short-term pretreatment with atorvastatin attenuates left ventricular dysfunction, reduces infarct size and apoptosis in acute myocardial infarction rats.
Int J Clin Exp Med
. 2014 Dec; 7(12): 4799–808.
52.
Yang JH, Xie LS, Guo Z. Adaptive response to stress of acute myocardial infarction leads to apoptosis of retinal cells of rats.
Neurosci Lett
. 2011 Jan; 487(1): 110–2.
53.
Bernstein SA, Morley GE. Gap junctions and propagation of the cardiac action potential.
Adv Cardiol
. 2006; 42: 71–85.
54.
Chanson M, Kotsias BA, Peracchia C, O’Grady SM. Interactions of connexins with other membrane channels and transporters.
Prog Biophys Mol Biol
. 2007 May-Jun; 94(1-2): 233–44.
55.
Meij JT, Panagia V, Mesaeli N, Peachell JL, Afzal N, Dhalla NS. Identification of changes in cardiac phospholipase C activity in congestive heart failure.
J Mol Cell Cardiol
. 1997 Jan; 29(1): 237–46.
56.
Hamzic N, Blomqvist A, Nilsberth C. Immune-induced expression of lipocalin-2 in brain endothelial cells: relationship with interleukin-6, cyclooxygenase-2 and the febrile response.
J Neuroendocrinol
. 2013 Mar; 25(3): 271–80.
57.
Eilenberg W, Stojkovic S, Piechota-Polanczyk A, Kaun C, Rauscher S, Gröger M, et al. Neutrophil gelatinase-associated lipocalin (NGAL) is associated with symptomatic carotid atherosclerosis and drives pro-inflammatory state in vitro.
Eur J Vasc Endovasc Surg
. 2016 May; 51(5): 623–31.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.